Branded versus generic clopidogrel in cardiovascular diseases: A systematic review

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 4, 2013, Pages 277-282

  Caldeira, Daniel ^a   Fernandes, Ricardo M ^a   Costa, João ^a   David, Cláudio ^a   Sampaio, Cristina ^a,b   Ferreira, Joaquim J ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

brand; cardiovascular; clopidogrel; generic; Plavix

Indexed keywords

CLOPIDOGREL; GENERIC DRUG;

ANGINA PECTORIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUGS, GENERIC; HUMANS; PATENTS AS TOPIC; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84876412183     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827e5c60     Document Type: Review

References (46)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339
2. Budaj A, Yusuf S, Mehta SR, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-1626
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189
4. Chen ZM, Jiang LX, Chen YP, et al COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebocontrolled trial. Lancet. 2005;366:1607-1621
5. Mehta SR, Tanguay JF, Eikelboom JW, et al; CURRENT-OASIS 7 Trial Investigators. Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet. 2010;376:1233-1243
6. Bhatt DL, Flather MD, Hacke W, et al CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988
7. Steinhubl SR, Berger PB, Mann JT III, et al CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420
8. Setiawati E, Yunaidi DA, Handayani LR, et al. Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers. Arzneimittelforschung. 2011;61:681-684
9. Shim CY, Park S, Song JW, et al. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. Clin Ther. 2010;32:1664-1673
10. Di Girolamo G, Czerniuk P, Bertuola R, et al. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010;32:161-170
11. Müller A, Octavio J, González MY, et al. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: A clinical trial. Am J Ther. 2010;17:351-356
12. El Ahmady O, Ibrahim M, Hussein AM, et al. Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers. Int J Clin Pharmacol Ther. 2009;47:780-784
13. Filipe A, Almeida S, Franco Spínola AC, et al. Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 2009;47:187-194
14. Kummer O, Roffi M, Marti G, et al. Clopidogrel and its salts: Any clinical implication?. Rev Med Suisse. 2010;6:1127-1128
15. Committee for Medicinal Products for Human Use. May 2009 plenary meeting monthly report. Available at: Http://www.emea.europa.eu/docs/en-GB/ document-library/Committee-meeting-report/2009/10/WC500005831.pdf. Accessed May 23, 2012
16. Generic clopidogrel besilate makes inroads into European Plavix market. Available at: Http://cardiobrief.org/2010/01/21/generic-clopidogrel- besilatemakes- inroads-into-european-plavix-market/#more-4375. Accessed May 23, 2012
17. Department of Health. The proposals to implement'generic substitution'
18. in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009. Available at: Http://www.dh.gov.uk/en/Consultations/ Liveconsultations/DH-110517. Accessed May 23, 2012
19. Shuchman M. Delaying generic competition - corporate payoffs and the future of Plavix. N Engl J Med. 2006;355:1297-1300
20. Bristol-Myers Squibb and sanofi-aventis announce U.S. FDA decision to grant pediatric exclusivity for PLAVIX-. Available at: Http://www.sanofi- aventis. ph/l/ph/en/download.jsp?file=D5F3060C-C299-4074-89FE-E4393B6D431F. pdf. Accessed May 23, 2012
21. IMS Health. The use of medicines in the United States: Review of 2010 National Sales Perspectives, Dec 2010. Available at: Http://www. imshealth.com/imshealth/Global/Content/IMS Institute/Documents/ IHII-UseOfMed-report.pdf. Accessed May 23, 2012
22. Bristol Myers Squibb anticipates significant decline in sales in the US for clopidogrel. Available at: Http://www.prweb.com/releases/2012/5/ prweb9508535.htm. Accessed May 23, 2012
23. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration. 2011:chap 8. Available at: Www.cochrane-handbook.org
24. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site. Available at: Http://www.ohri. ca/programs/ clinical-epidemiology/oxford.htm. Accessed May 23, 2012
25. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575-1600
26. Deeks JJ, Higgins JPT, Altman DG, eds. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration; 2011:chap 9
27. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. London, United Kingdom: BMJ Publication Group; 2001:313-335
28. Suh JW, Seung KB, Gwak CH, et al. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: A phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. Clin Ther. 2011;33:1057-1068
29. Khosravi AR, Pourmoghadas M, Ostovan M, et al. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study. J Res Med Sci. 2011;16:640-650
30. Avdeeva LV, Shtegman OA, Mosina VA. Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting. Kardiologiia. 2011;51:23-26
31. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA. 2008;300:2514-2526
32. van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: A methodological systematic review. PLoS One. 2011;6:e23611
33. FDA guidance for industry - bioavailability and bioequivalence studies for orally administered drugs products - general considerations. Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070124.pdf. Accessed May 23, 2012
34. EMEA Committee for Medicinal Products for Human Use (CMPH). Guideline on the investigation of bioequivalence. Available at: Http://www.ema. europa.eu/pdfs/human/qwp/140198enrev1fin.pdf. Accessed May 23, 2012
35. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis. Drugs. 2010;70:605-621
36. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ. 2003; 326:1167-1170
37. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ. 2006;333:782
38. Himmel W, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43:472-479
39. Kjoenniksen I, Lindbaek M, Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28:284-289
40. Heikkilä R, Mäntyselkä P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20:185-191
41. Heikkilä R, Mäntyselkä P, Ahonen R. Price, familiarity, and availability determine the choice of drug - a population-based survey five years after generic substitution was introduced in Finland. BMC Clin Pharmacol. 2011;11:20
42. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-337
43. Ho PM, Tsai TT, Maddox TM, et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: Implications for transitions of care. Circ Cardiovasc Qual Outcomes. 2010;3:261-266
44. Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis. 2010;103:363-375
45. Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008;359: 1802-1810
46. Van Wijk BL, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: Does it affect adherence? Ann Pharmacother. 2006;40:15-20